ClinicalTrials.gg
Active, not recruitingNCT06372925V-ACCELERATEUpdated Jul 28, 2026

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction

A Phase 4 interventional study of atorvastatin and IVUS/OCT in Plaque, Atherosclerotic, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 19 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Plaque, Atherosclerotic with a site in China — 7 open to participants now, 9 under way, 2 of them phase 3. Plaque, Atherosclerotic · China.

Started
2024
the only one that year
Phase 4
3 of 13
2 open now
Registered
9th of 13
by date
Lead sponsor
3 of 13
Novartis Pharmaceuticals

Among the 13 studies in Plaque, Atherosclerotic with a site in China, this one is the only one that started in 2024, is one of 3 in phase 4, and was the 9th registered.

Plaque, Atherosclerotic

105 studies on the registry are indexed under Plaque, Atherosclerotic; 27 are open to participants now.

Browse Plaque, Atherosclerotic studies →

Open to participants now

7 of the 13 studies in Plaque, Atherosclerotic with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Plaque, Atherosclerotic studies recruiting now, 7 (44%) set no upper age limit and 4 (25%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Plaque, Atherosclerotic with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the effect of Inclisiran on coronary atherosclerosis using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in patients with acute myocardial infarction and elevated low-density lipoprotein cholesterol (LDL-C).

Read the detailed description

This study will be a multi-center, randomized, parallel-group, open-label, phase 4 study. Participants will be Chinese adults diagnosed with new-onset STEMI/NSTEMI and elevated LDL-C (LDL-C > 1.8 mmol/L if on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks; LDL-C > 2.6 mmol/L if not on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks). Participants will be 1:1 randomized to investigational group (Inclisiran 284mg + 20mg atorvastatin) or control group (20mg atorvastatin) for 360 days. Participants and investigator will be unblinded to the identity of the treatment from the time of randomization. Independent Review Committee (IRC) staff performing the study assessments (IVUS and OCT analysis) will be blinded to the identity of the treatment from the time of randomization until final database lock.

03

Conditions studied

  • Plaque, Atherosclerotic

Keywords

  • Acute myocardial infarction,
  • Atherosclerotic plaque,
  • Inclisiran,
  • IVUS,
  • OCT,
  • PCI
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 and ≤ 75 years of age.
  2. Acute myocardial infarction (STEMI ≤ 24h/NSTEMI ≤ 72h of onset of symptoms) with planned PCI.
  3. At least 1 major, non-infarct-related coronary artery ("target vessel") meet all of the following criteria judged by the investigator:

1) Presence of atherosclerotic plaque with ≥ 20% and ≤ 50% diameter stenosis by coronary angiography.

2) Target vessel deemed to be accessible to imaging catheters and suitable for intravascular imaging in the proximal (50 mm) segment ("target segment") 3) Target vessel is suitable for IVUS and OCT evaluation. 4) Not have undergone previous PCI within target vessel. 5) Not be a bypass graft or a bypassed native vessel. 4. Rapid LDL-C test value at screening period of:

  1. LDL-C > 1.8 mmol/L if on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks upon signing ICF.
  2. LDL-C > 2.6 mmol/L if not on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks upon signing ICF.

5. Written must be obtained.

Exclusion criteria

Exclusion Criteria:

  1. Familial hypercholesterolemia or secondary hypercholesterolemia.
  2. Clinically instable AMI (hemodynamic or electrical instability).
  3. Left main disease, defined as ≥ 50% diameter stenosis of the left main coronary artery by coronary angiography.
  4. Three-vessel disease, defined as ≥ 70% diameter stenosis of 3 major epicardial coronary vessels or in major branches of these arteries by coronary angiography.
  5. Have a plan for interventional procedure within 12 months after signing ICF.
  6. Known intolerance to Atorvastatin OR known statin intolerance.
  7. Patients already on high-intensity statin including atorvastatin 40 or 80 mg or rosuvastatin 20 mg upon signing ICF.
  8. Patients not suitable for IVUS/OCT evaluation (e.g., significant calcification , etc) judged by the investigator.
  9. Patients qualify for coronary artery bypass surgery at screening and history of coronary artery bypass surgery.
  10. Cardiac disorders:

1) Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening; 2) Pacemaker or ICD in situ; and/or 3) Uncontrolled severe hypertension with systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization despite antihypertensive therapy.

11. Rapid lipid test triglyceride (TG) level > 400mg/dL (4.5 mmol/L) at screening.

12. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in (ALT), aspartate aminotransferase (AST), > 3x the (ULN), or total > 2x ULN before the randomization.

13. Estimated (eGFR) \< 30 mL/min/1.73m2(Calculated according to the modified MDRD equation).

14. Severe concomitant non-cardiovascular disease that carries the risk of reducing to less than 2 years.

15. Previous (within 90 days before randomization), current or planned treatment with a PCSK9 monoclonal antibody (mAb).

16. Previous exposure to Inclisiran or any other non-mAb PCSK9-targeted therapy 2 years prior to randomization.

17. Participation in another device or drug study currently, or within 5 half-live (if drug) or 30 days whichever is longer, prior to randomization.

18. History of to any study drug or its . 19. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study and/or put the participant at significant risk according to investigator's judgment.

20. Pregnant or nursing (lactating) women. 21. Women of , unless they are using effective methods of during study treatment.

22. Any conditions that according to the investigator could interfere with the conduct of the study.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    Inclisiran and atorvastatin

    Inclisiran 284mg SC (at D1,D90,D270)+ 20mg atorvastatin PO

    Drug: atorvastatin · Procedure: IVUS/OCT · Drug: inclisiran

  • Active comparator
    atorvastatin

    20mg atorvastatin PO

    Drug: atorvastatin · Procedure: IVUS/OCT

Interventions

  • 20mg atorvastatin PO

  • ProcedureIVUS/OCT

    performed the IVUS/OCT at baseline and Day 360

  • Inclisiran 284mg SC

06

What researchers measure

Primary outcomes

  1. Change in percent atheroma volume (PAV)

    Change in PAV assessed by intravascular ultrasound (IVUS) from baseline to Day 360.

    Time frame: Up to 360 days

Secondary outcomes

  1. Change in minimum fibrous cap thickness (FCT)

    Change in minimum FCT as determined by optical coherence tomography (OCT) from baseline to Day 360

    Time frame: Up to 360 days

  2. Change in mean minimum FCT of all images

    Change in mean minimum fibrous cap thickness (FCT) of all images as determined by OCT from baseline to Day 360.

    Time frame: 360 days

  3. Change in normalized total atheroma volume (NTAV)

    Change in NTAV as determined by intravascular ultrasound (IVUS) from baseline to Day 360

    Time frame: Up to 360 days

  4. Proportion of participants with progression, regression, or no change in PAV

    Proportion of participants with progression, regression, or no change in percent atheroma volume (PAV) at Day 360

    Time frame: Up to 360 days

  5. Change in LDL-C

    Change in low-density lipoprotein cholesterol (LDL-C)

    Time frame: Baseline, Day 30, Day 150 and Day 360

  6. Change in TC

    Change in total cholesterol (TC).

    Time frame: Baseline, Day 30, Day 150 and Day 360

  7. Change in HDL-C

    Change in high-density lipoprotein cholesterol (HDL-C).

    Time frame: Baseline, Day 30, Day 150 and Day 360

  8. Change in non-HDL-C

    Change in non-high-density lipoprotein cholesterol (non-HDL-C).

    Time frame: Baseline, Day 30, Day 150 and Day 360

  9. Change in ApoB

    Change in apolipoprotein B (ApoB).

    Time frame: Baseline, Day 30, Day 150 and Day 360

  10. Change in ApoA1

    Change in apolipoprotein A1 (ApoA1).

    Time frame: Baseline, Day 30, Day 150 and Day 360

  11. Change in Lp(a)

    Change in lipoprotein (a) (Lp(a))

    Time frame: Baseline, Day 30, Day 150 and Day 360

  12. Change in TG

    Change in triglycerides (TG)

    Time frame: Baseline, Day 30, Day 150 and Day 360

  13. Proportion of participants with LDL-C target attainment

    Proportion of participants with LDL-C target attainment at Day 30, Day 150, and Day 360

    Time frame: Day 30, Day 150 and Day 360

07

Study locations

19 sites
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Fuzhou, Fujian 350001, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510000, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518000, China
  • Novartis Investigative Site
    Zunyi, Guizhou 563000, China
  • Novartis Investigative Site
    Harbin, Heilongjiang 150086, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
  • Novartis Investigative Site
    Wuhan, Hubei 430060, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Changchun, Jilin 130033, China
  • Novartis Investigative Site
    Dalian, Liaoning 116023, China
  • Novartis Investigative Site
    Jining, Shandong 272000, China
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610072, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325027, China
  • Novartis Investigative Site
    Beijing, 101149, China
  • Novartis Investigative Site
    Lanzhou, 730000, China
  • Novartis Investigative Site
    Tianjin, 300000, China
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 18, 2024
StartActual
Jul 9, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jan 26, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06372925
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Jul 9, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Jan 26, 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion